Please login to the form below
aclidinium
This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.
Circassia seeks shift to AIM after failing LSE criteria
The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017. ... Duaklir (aclidinium/formoterol)
Latest news
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
-
GSK's triple COPD therapy tops Symbicort in phase III trial
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
-
GSK brings forward triple COPD therapy filing in US
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
-
Boehringer bags FDA approval for Spiriva-based combo
AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
-
GSK sees COPD future in triple therapy
Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.
Circassia exits allergy R&D after placebo effect strikes again
GSK's triple COPD therapy tops Symbicort in phase III trial
Boehringer bags FDA approval for Spiriva-based combo
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Interview: Jorge Gallardo, Almirall
We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive
Interview: Jorge Gallardo, Almirall
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO, Head of Health, UK
-
Six figure salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- Valneva COVID-19 vaccine more effective than AZ
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
No results were found
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
